- Edesa Biotech (EDSA +3.1%), receives FDA clearance to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for treatment of Covid-19.
- EB05 is an experimental monoclonal antibody that the company believes could regulate the overactive immune response associated with Acute Respiratory Distress Syndrome pr ARDS - the leading cause of death in COVID-19 patients.
- The company has begun the site initiation process at U.S. hospitals.
- Press Release
- https://seekingalpha.com/news/3623274-edesa-receives-fda-approval-to-initiate-covid-studies-in-us
Monday, October 19, 2020
Edesa receives FDA approval to initiate Covid studies in the US
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.